Proteomic mass spectrometry data - Prostate cancer serum samples - raw data

Raw data from HDMSe and SWATH MS analyses of 309 prostate cancer serum samples. Prostate cancer cohort:   

309 patients were divided into control (n=112), prostate cancer (PCa) (n=175), and benign prostate hyperplasia (BPH) (n=22). PCa patients were then subdivided into active surveillance (AS) (n=51) or treatment group. Treatments were radiotherapy (pre: n=26, post: n=14), hormone therapy (pre: n=7, post: n=8), prostatectomy (pre: n=21, post: n=8), and radiotherapy (pre: n=23, post: n=17)